Journal of Endocrinological Investigation

, Volume 41, Issue 5, pp 591–596 | Cite as

Deregulation of the growth hormone/insulin-like growth factor-1 axis in adults with cystic fibrosis

  • C. Pascucci
  • R. V. De Biase
  • D. Savi
  • S. Quattrucci
  • A. M. Isidori
  • C. Lubrano
  • L. Gnessi
  • A. Lenzi
Original Article
  • 56 Downloads

Abstract

Purpose

Patients with cystic fibrosis (CF) present with signs and symptoms that overlap with those of adult growth hormone deficiency (GHD) syndrome: loss of muscle mass, bone fragility and lower stress tolerance. In literature, the prevalence of GHD in pediatric CF patients is higher than general population, but these studies have been performed on children with growth delay. To our knowledge, there are no studies on adult patients. The aim of this paper is to evaluate GH–IGF1 axis in an adult CF population.

Methods

Fifty clinically stable adult patients, 30 males; age 36 ± 2 years; BMI 21.39 ± 0.22 kg/m2 and FEV1 67 ± 4% were studied. Data regarding glycometabolic status and results of pituitary, thyroid, parathyroid, gonadal and adrenal function tests were recorded. All patients underwent a GH releasing hormone (GHRH) + Arginine stimulation test to confirm a GHD.

Results

GHRH + Arginine test revealed the presence of GHD in 16 patients (32%); specifically 7 patients had a severe deficiency and 9 a partial deficiency.

Conclusions

Adult patients with CF may show GHD. These patients should be followed over time to assess if the GHD could impact the clinical progression of CF.

Keywords

Growth hormone deficiency Insulin-like growth factor-1 Cystic fibrosis Adult patients 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest in this work.

Ethical approval

The present study was approved by the ethics committee of the University and adhered to the tenets of the Declaration of Helsinki.

Informed consent

Additionally, the written informed consents were signed by all participants.

References

  1. 1.
    Fajac I, De Boeck K (2017) New horizons for cystic fibrosis treatment. Pharmacol Ther 170:205–211CrossRefPubMedGoogle Scholar
  2. 2.
    Cystic Fibrosis Foundation (2015) Patient Registry Annual Data ReportGoogle Scholar
  3. 3.
    Hardin DS (2007) A review of the management of two common clinical problems found in patients with cystic fibrosis: cystic fibrosis-related diabetes and poor growth. Horm Res 68(Suppl 5):113–116PubMedGoogle Scholar
  4. 4.
    Blackman SM, Tangpricha V (2016) Endocrine disorders in cystic fibrosis. Pediatr Clin N Am 63(4):699–708CrossRefGoogle Scholar
  5. 5.
    Mauras N (2001) Growth hormone therapy in the glucocorticosteroid dependent child: metabolic and linear growth effects. Horm Res 56(Suppl 1):13–18PubMedGoogle Scholar
  6. 6.
    Sinha A, Hollingsworth KG, Ball S, Cheetham T (2014) Impaired quality of life in growth hormone—deficient adults is independent of the altered skeletal muscle oxidative metabolism found in conditions with peripheral fatigue. Clin Endocrinol (Oxf) 80(1):107–114CrossRefGoogle Scholar
  7. 7.
    De Boer H, Blok GJ, Van der Veen EA (1995) Clinical aspects of growth hormone deficiency in adults. Endocr Rev 16:63–86CrossRefPubMedGoogle Scholar
  8. 8.
    Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P, Meta-analysis of Blinded, Randomized, Placebo-Controlled Trials (2004) Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Meta-analysis of Blinded, Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab 89(5):2192–2199CrossRefPubMedGoogle Scholar
  9. 9.
    Woodhouse LJ, Mukherjee A, Shalet SM, Ezzat S (2006) The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocr Rev 27(3):287–317CrossRefPubMedGoogle Scholar
  10. 10.
    Van Bunderen CC, Van Varsseveld NC, Erfurth EM, Ket JC, Drent ML (2014) Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity. Clin Endocrinol (Oxf) 81(1):1–14CrossRefGoogle Scholar
  11. 11.
    Ciro D, Padoan R, Blau H, Marostica A, Fuoti M, Volpi S, Pilotta A, Meyerovitch J, Sher D, Assael BM (2013) Growth retardation and reduced growth hormone secretion in cystic fibrosis. Clinical observations from three CF centers. J Cyst Fibros 12(2):165–169CrossRefPubMedGoogle Scholar
  12. 12.
    Laursen EM, Lanng S, Rasmussen MH, Koch C, Skakkebaek NE, Müller J (1999) Normal spontaneous and stimulated GH levels despite decreased IGF-I concentrations in cystic fibrosis patients. Eur J Endocrinol 140(4):315–321CrossRefPubMedGoogle Scholar
  13. 13.
    Scaparrotta A, Di Pillo S, Attanasi M, Consilvio NP, Cingolani A, Rapino D, Mohn A, Chiarelli F (2012) Growth failure in children with cystic fibrosis. J Pediatr Endocrinol Metab 25(5–6):393–405PubMedGoogle Scholar
  14. 14.
    Wong SC, Dobie R, Altowati MA, Werther GA, Farquharson C, Ahmed SF (2016) Growth and the growth hormone insulin like growth factor 1 axis in children with chronic inflammation: current evidence, gaps in knowledge, and future directions. Endocr Rev 37(1):62–110CrossRefPubMedGoogle Scholar
  15. 15.
    Thaker V, Haagensen AL, Carter B, Fedorowicz Z, Houston BW (2013) Recombinant growth hormone therapy for cystic fibrosis in children and young adults. Cochrane Database Syst Rev (6):1–117Google Scholar
  16. 16.
    Phung OJ, Coleman CI, Baker EL, Scholle JM, Girotto JE, Makanji SS, Chen WT, Talati R, Kluger J, White CM (2010) Recombinant human growth hormone in the treatment of patients with cystic fibrosis. Pediatrics 126(5):1211–1226CrossRefGoogle Scholar
  17. 17.
    Poggi M, Pascucci C, Monti S, Pugliese P, Lauri C, Amodeo G, Girelli G, Toscano V (2010) Prevalence of growth hormone deficiency in adult polytransfused β-thalassemia patients and correlation with transfusional and chelation parameters. J Endocrinol Invest 33(8):534–538CrossRefPubMedGoogle Scholar
  18. 18.
    Ballinger A (2002) Fundamental mechanisms of growth failure in inflammatory bowel disease. Horm Res 58(Suppl 1):7–10PubMedGoogle Scholar
  19. 19.
    Sermet-Gaudelus I, Souberbielle JC, Azhar I, Ruiz JC, Magnine P, Colomb V, Le Bihan C, Folio D, Lenoir G (2003) Insulin-like growth factor I correlates with lean body mass in cystic fibrosis. Arch Dis Child 88(11):956–961CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Giustina A, Mazziotti G, Canalis E (2008) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29(5):535–559CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Davidson P, Milne R, Chase D, Cooper C (2004) Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 60(1):92–98CrossRefGoogle Scholar
  22. 22.
    Doga M, Bonadonna S, Gola M, Mazziotti G, Nuzzo M, Giustina A (2005) GH deficiency in the adult and bone. J Endocrinol Invest 28(8 Suppl):18–23 (Review) PubMedGoogle Scholar
  23. 23.
    Casanueva FF, Castro AI, Micic D, Kelestimur F, Dieguez C (2009) New guidelines for the diagnosis of growth hormone deficiency in adults. Horm Res 71(Suppl 1):112–115PubMedGoogle Scholar
  24. 24.
    Corneli G, Di Somma C, Baldelli R, Rovere S, Gasco V, Croce CG, Grottoli S, Maccario M, Colao A, Lombardi G, Ghigo E, Camanni F, Aimaretti G (2005) The cut-off limits of the GH response to GH-releasing hormone—arginine test related to body mass index. Eur J Endocrinol 153(2):257–264CrossRefPubMedGoogle Scholar
  25. 25.
    Yuen KC, Tritos NA, Samson SL, Hoffman AR, Katznelson L (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical review: update on growth hormone stimulation testing and proposed revised cut-point for the Glucagon stimulation test in the diagnosis of adult growth hormone deficiency. Endocr Pract 22(10):1235–1244 (Epub 2016 jul 13) CrossRefPubMedGoogle Scholar
  26. 26.
    Herschbach P, Henrich G, Strasburger CJ, Feldmeier H, Marín F, Attanasio AM, Blum WF (2001) Development and psychometric properties of a disease-specific quality of life questionnaire for adult patients with growth hormone deficiency. Eur J Endocrinol 145(3):255–265CrossRefPubMedGoogle Scholar
  27. 27.
    Colao A, Di Somma C, Cascella T, Pivonello R, Vitale G, Grasso LFS, Lombardi G, Savastano S (2008) Relationships between serum IGF-1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol 159:389–397CrossRefPubMedGoogle Scholar
  28. 28.
    Shen Y, Zhang J, Zhao Y, Yan Y, Liu Y, Cai J (2015) Diagnostic value of serum IGF-1 and IGFBP-3 in growth hormone deficiency: a systematic review with meta-analysis. Eur J Pediatr 174(4):419–427CrossRefPubMedGoogle Scholar
  29. 29.
    Livingstone C, Borai A (2014) Insulin-like growth factor-II: its role in metabolic and endocrine disease. Clin Endocrinol (Oxf) 80(6):773–781CrossRefGoogle Scholar
  30. 30.
    Bach LA (2015) Insulin-like growth factor binding proteins 4–6. Best Pract Res Clin Endocrinol Metabol 29(5):713–722CrossRefGoogle Scholar
  31. 31.
    Hjortebjerg R, Frystyk J (2013) Determination of IGFs and their binding proteins. Best Pract Res Clin Endocrinol Metab 27(6):771–781CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2017

Authors and Affiliations

  1. 1.Section of Medical Pathophysiology, Endocrinology, Department Experimental MedicineSapienza UniversityRomeItaly
  2. 2.Pediatrics Department, Cystic Fibrosis Regional CenterSapienza University of RomeRomeItaly
  3. 3.Cystic Fibrosis UnitIRCCS Ospedale Pediatrico Bambino GesùRomeItaly

Personalised recommendations